MyFinsight
Home
Blog
About
Cash and cash
equivalents, including...
$66,740K
(10.36%↑ Y/Y)
Inventories
$20,640K
(43.27%↑ Y/Y)
Trade receivables,
net of allowances of...
$8,580K
(-11.14%↓ Y/Y)
Prepaid expenses and
other assets
$1,826K
(-14.79%↓ Y/Y)
Total current assets
$97,786K
(12.81%↑ Y/Y)
Intangible assets, net
$5,311K
(1770.07%↑ Y/Y)
Right-of-use assets, net
$1,840K
(-27.13%↓ Y/Y)
Leasehold improvements
and equipment, net
$1,247K
(-23.59%↓ Y/Y)
Other long-term
assets
$405K
(0.00%↑ Y/Y)
Total assets
$106,589K
(16.46%↑ Y/Y)
Total liabilities and
stockholders' equity
$106,589K
(16.46%↑ Y/Y)
Total stockholders'
equity
$82,528K
(28.56%↑ Y/Y)
Total liabilities
$24,061K
(-11.96%↓ Y/Y)
Accumulated deficit
-$157,247K
(9.23%↑ Y/Y)
Cumulative translation
adjustments
-$2K
(50.00%↑ Y/Y)
Additional paid-in capital
$239,698K
(0.99%↑ Y/Y)
Total current
liabilities
$15,050K
(-32.59%↓ Y/Y)
Deferred consideration
liability, less current...
$5,165K
Deferred revenue
$2,434K
(-8.98%↓ Y/Y)
Operating lease
obligations, less current...
$1,412K
(-39.37%↓ Y/Y)
Common stock, 0.001 par
value authorized...
$79K
(0.00%↑ Y/Y)
Accounts payable
$9,439K
(-31.00%↓ Y/Y)
Accrued expenses
$3,841K
(-47.96%↓ Y/Y)
Current maturities of
operating lease...
$917K
(-4.18%↓ Y/Y)
Current deferred
consideration liability
$524K
Customer deposits
$329K
(8.58%↑ Y/Y)
Back
Back
Balance Sheet
Niagen Bioscience, Inc. (NAGE)
Niagen Bioscience, Inc. (NAGE)
source: myfinsight.com